Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
85 hedge funds and large institutions have $124M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 20 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more call options, than puts
Call options by funds: $301K | Put options by funds: $267K
8% less funds holding
Funds holding: 92 → 85 (-7)
18% less capital invested
Capital invested by funds: $151M → $124M (-$26.9M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.32M |
| 2 |
Morgan Stanley
New York
|
+$2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.44M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.16M |
| 5 |
6CM
683 Capital Management
New York
|
+$806K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$3M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.43M |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
-$911K |
| 4 |
Renaissance Technologies
New York
|
-$888K |
| 5 |
Two Sigma Advisers
New York
|
-$498K |
EIGR Hedge Fund Activity: Q4 2021 in Review
85 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2021, worth a combined $124M — down 18% from $151M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of EIGR and 15 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was Ameriprise, adding an estimated $7.32M. The largest seller was Vivo Capital, cutting an estimated $3M.
- 85 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2021, down from 92 in Q3 2021.
- Funds reported $124M of Eiger BioPharmaceuticals, Inc. stock for Q4 2021, down 18% quarter-over-quarter.
- 15 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2021 and 20 closed out, a net change of -5 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2021 was Ameriprise, an estimated $7.32M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2021 was Vivo Capital, an estimated $3M sold.
Based on aggregated 13F filings for Q4 2021.